CRP and depressive symptom measurement: In addition, an interim analysis from an ongoing randomized placebo-controlled study with enoxolone, 100 mg vs. placebo, in hospitalized patients with depression [269], confirmed target engagement by a significant reduction in the night urine aldosterone/cortisol ratio and of plasma CRP.